Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor

Abstract : Because of the complex biological networks, many pathologic disorders fail to be treated with a molecule directed towards a single target. Thus, combination therapies are often necessary, but they have many drawbacks. An alternative consists in building molecules intended to interact with multiple targets, called designed multiple ligands. We followed such a strategy in order to treat metabolic syndrome, by setting up molecules directed towards both type 1 angiotensin II (AT 1) receptor and peroxisome proliferator-activated receptor-γ (PPAR-γ). For this purpose, many molecules were prepared by merging both pharmacophores following three different strategies. Their ability to activate PPAR-γ and to block AT 1 receptors were evaluated in vitro. This strategy led to the preparation of many new PPAR-γ activating and AT 1 blocking molecules. Among them, some exhibited both activities, highlighting the convenience of this approach.
Document type :
Journal articles
Complete list of metadatas

Cited literature [61 references]  Display  Hide  Download

https://hal.univ-lorraine.fr/hal-01905470
Contributor : Michel Boisbrun <>
Submitted on : Tuesday, November 20, 2018 - 10:53:23 AM
Last modification on : Tuesday, November 5, 2019 - 11:06:46 AM

Identifiers

Citation

Maxime Meyer, Sébastien Foulquier, François Dupuis, Stéphane Flament, Linda Grimaud, et al.. Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor. European Journal of Medicinal Chemistry, Elsevier, 2018, 158, pp.334-352. ⟨10.1016/j.ejmech.2018.08.082⟩. ⟨hal-01905470⟩

Share

Metrics

Record views

155

Files downloads

32